Post by Dicot Pharma AB

Dicot Pharma is taking an important step toward advancing LIB-01 into a clinical phase 2b study. The company intends to carry out a rights issue of approximately SEK 210 million, already secured to 80%, to finance the next stage of clinical development. This reflects continued confidence in the program and in the long-term value creation potential ahead of future partnering and licensing discussions. ”We are seeing significant interest in our drug candidate in dialogues with investors and potential licensees. Naturally, we are keen to protect our existing shareholders while at the same time capturing the interest from new investors, including international, which is very positive. Another important strategic aspect is to carefully select the right timing for licensing deals in order to maximize shareholder value. Against this background, we have concluded that we should carry out this rights issue with a structure that gives priority to existing shareholders while also providing new investors with the opportunity to participate. The amount secured corresponds to a fully financed phase 2b study, which enables us to continue building value in accordance with our strategic plan,” says Eva Sjökvist Saers, Chair of the Board of Dicot Pharma. The notice of the Annual General Meeting on May 6, 2026 proposes an authorization that may be used for the Board of Directors resolution on the Issue. https://lnkd.in/dXVC24mX